Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Oncology
3
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
2100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
Axicabtagene CiloleucelPhase 3Cell Therapy1 trial
Axicabtagene CiloleucelPhase 3Cell Therapy
Active Trials
NCT03391466Completed359Est. Nov 2024
Antengene
AntengeneChina - Shanghai
1 program
1
ATG-010 60 mg, orally, twice weekly, each 4 weekPhase 21 trial
Active Trials
NCT03992339CompletedEst. Dec 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Gilead SciencesAxicabtagene Ciloleucel
AntengeneATG-010 60 mg, orally, twice weekly, each 4 week

Clinical Trials (2)

Total enrollment: 359 patients across 2 trials

NCT03391466Gilead SciencesAxicabtagene Ciloleucel

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Start: Jan 2018Est. completion: Nov 2024359 patients
Phase 3Completed
NCT03992339AntengeneATG-010 60 mg, orally, twice weekly, each 4 week

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: Apr 2020Est. completion: Dec 2023
Phase 2Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
Cell Therapy is the dominant modality (100% of programs)
2 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)